Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 218.66M P/E - EPS this Y - Ern Qtrly Grth -
Income -94.9M Forward P/E -2.02 EPS next Y -15.90% 50D Avg Chg -27.00%
Sales 2.07M PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.00 EPS next 5Y - 52W High Chg -44.00%
Recommedations 2.80 Quick Ratio 14.66 Shares Outstanding 84.87M 52W Low Chg 60.00%
Insider Own 0.47% ROA -24.57% Shares Float 63.17M Beta -0.72
Inst Own 79.10% ROE -49.34% Shares Shorted/Prior 4.86M/7.92M Price 3.18
Gross Margin - Profit Margin - Avg. Volume 49,669 Target Price 21.67
Oper. Margin -4,798.45% Earnings Date May 9 Volume 24,743 Change -2.91%
About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Fusion Pharmaceuticals Inc. News
04/26/24 Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
04/25/24 Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
04/23/24 Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
04/17/24 Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know
04/11/24 Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
04/11/24 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the company
04/09/24 Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
03/22/24 Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
03/20/24 Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
03/20/24 Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
03/20/24 AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
03/19/24 These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, Fusion Pharmaceuticals, Nordstrom, International Paper, Tesla, and More
03/19/24 Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover
03/19/24 Stocks to Watch Tuesday: Super Micro, Fusion Pharmaceuticals, Nvidia, Unilever
03/19/24 These Stocks Are Moving the Most Today
03/19/24 Fusion Pharmaceuticals Stock Soars. It’s Being Acquired by AstraZeneca in $2.4 Billion Deal.
03/19/24 Super Micro, XPeng, AstraZeneca: Trending tickers
03/19/24 Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal
03/19/24 AstraZeneca buys Canadian cancer treatment firm for close to £2bn
03/19/24 AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
FUSN Chatroom

User Image Stock_Titan Posted - 04/25/24

$FUSN Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-mails-circular-for-special-meeting-of-8b0yg3hpnzo2.html

User Image Gbornste Posted - 04/24/24

@Darkness746262 I’d like to believe we are worth more than $FUSN

User Image Corona_My_Sharona Posted - 04/23/24

$FUSN.................. https://www.forbes.com/sites/jakezamansky/2013/08/08/the-great-vampire-squid-keeps-on-sucking/?sh=47c5415e7df8

User Image TickerDD_com Posted - 04/23/24

From 4/12/2024, looking back across 22 Month-Ends for FUSN, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had All Positives (100%) $FUSN #FUSN #FUSNStock #TickerDD https://www.youtube.com/watch?v=KIPpgxuqxlQ

User Image Mergerbrief Posted - 04/22/24

$FUSN $AZN - HSR possibly expires MergerBrief.com

User Image Braverabbit Posted - 04/18/24

$FUSN The One Stock to buy now. Please do your own DD and feel free to read my posts re: $VERU I will answer questions on that board.

User Image RonIsWrong Posted - 04/14/24

$ALPN $XBI $MRUS $SWTX $FUSN FUSN ☑️ ALPN ☑️ SNDX _?_ SWTX - bring it !! KRYS _?_

User Image Bobby_J_Bomb Posted - 04/13/24

$AADI opened up another $50k in case this tanks with markets. $FUSN is best example of a comparqble that had similar price action before data brought it back and culminated in a $2.4 bn buyout. AADI probably best r/r in bio right now with tsc1 and tsc2 data read in q3, registrational study for.multi-billion market complete by end of 2024 and rwsdout in early 2025....all while trading at 0.40 price/cash and runway through registrational final and other phase 2 studies in endometrial and neuroendocrine mutations. Best part is that the commercial application for tsc1 and tsc2 mutations in PEComa is based on the same MOA and early results are trending the same. Also, 3 year follow up data shows results are even better over a longer timeframe and confirm efficacy absolutely!!

User Image Ndziyy Posted - 04/11/24

@Paytient that’s because us dummies have diamond hands. That buy out is coming and we will be laughing. If $CATX hits like $FUSN did it will feed us for a bit haha

User Image ViractaTrader77 Posted - 04/10/24

$STRO $PYXS $FUSN $AMAM Sutro Bio could be next on big Pharma list. Immunogen and Profound Bio are similar to sutro’s lead ADC Luvelta in that it binds to the folate receptor. https://www.investopedia.com/genmab-buys-profoundbio-for-usd1-8b-to-boost-oncology-portfolio-8624021

User Image Ndziyy Posted - 04/10/24

@Jcljack26 I moved form $FUSN when it doubled to $CATX in hopes. I do believe it has that potential with all the interest this year

User Image Punkins Posted - 04/10/24

$FUSN Great prelim results for late stage prostate cancer.

User Image Stock_Titan Posted - 04/09/24

$FUSN Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-announces-presentation-of-interim-data-from-bmbdajfr8wki.html

User Image matmasr Posted - 04/07/24

Market Leaders between $20 and $50 with the highest TradeIdeas Composite Score. In times like these, you may want to watch for bounces on these leaders. $GLNG $ACMR $FUSN $VNOM and more. Get this scanner and other amazing features of TradeIdeas here https://go.trade-ideas.com/SHpg

User Image WizeKing44 Posted - 04/07/24

@wetsalmon @MK_bio is this company on par with $atnm and $fusn ?

User Image Biotrader2 Posted - 04/05/24

$CATX what’s the MC now ? I think $fusn get acquired for 2B .

User Image JoeSpringer Posted - 04/05/24

Next 10X Takeout in Hot New Area: youtube.com/live/cyCLgz5s2KY $FUSN $GLUE $IBB $SAVA $XBI

User Image JoeSpringer Posted - 04/04/24

Next 10X Takeout in Hot New Area 10 am ET Stream Action: https://youtube.com/live/cyCLgz5s2KY $FUSN $GLUE $IBB $SAVA $XBI

User Image Braverabbit Posted - 04/03/24

@mrrosewater89 You're welcome! I looked for this Biotech after I saw $FUSN get BO recently and then understood a lot more about this sector.

User Image GreenEnergy2022 Posted - 04/02/24

$BMEA Promising so far, its a long hold with great potential for $ $AKBA $ALT $FUSN

User Image JoeSpringer Posted - 03/31/24

The Next Quick 10X Takeout Is... https://multibaggersvip.substack.com/p/the-next-10x-takeout-is $FUSN $IBB $LABU $TQQQ $XBI

User Image SkiDean Posted - 03/31/24

$FUSN too late buying this

User Image fzr8 Posted - 03/27/24

$FUSN The party is over here. Take a look at other clubs.😂😂😂

User Image Punkins Posted - 03/27/24

$FUSN why would it go down, its been bought out

User Image Ktana25 Posted - 03/27/24

$FUSN is it ever going down

User Image StormChaser Posted - 03/26/24

@chunkamunk was there a leak with $FUSN?

User Image JakeDelToro Posted - 03/26/24

@Johnmtnb2018 @cb5000calls or MMs/Tutes keep it low so that when the run and offer occurs, it’s not retail holding the shares. $FUSN just got bought out as well and it was less than 8% retail ownership at buyout date.

User Image fzr8 Posted - 03/26/24

$ALT Well you could find similarities with $FUSN where it dropped like 30% before a buyout. Idk if Alt is going to BO but I am simply pouring some positive thoughts into my dark life.🤕🌚🤕

User Image HUSA_TO_100 Posted - 03/25/24

$ATOS Don’t be surprised if this gets BO by some big pharma after its Phase 2 Data✅ $LABP got takeover by $ABBV today while $FUSN got acquired by $AZN a week ago. Bios are getting BO left and right by big Pharmas this year🔥

User Image Stockingisland Posted - 03/25/24

$GMDAQ nice to see $FUSN at a fixed price of $21 after their buyout.

Analyst Ratings
TD Cowen Hold Apr 16, 24
RBC Capital Sector Perform Mar 21, 24
Wedbush Neutral Mar 21, 24
Raymond James Market Perform Mar 20, 24
B. Riley Securities Neutral Mar 20, 24
Truist Securities Hold Mar 20, 24
RBC Capital Sector Perform Mar 20, 24
JonesTrading Hold Mar 20, 24
Truist Securities Hold Mar 19, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GANNON STEVEN Director Director Aug 11 Buy 2.03 44,400 90,132 56,400 08/11/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 20 Sell 6.02 1,289 7,760 326,841 04/22/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 11 Sell 6.96 32,849 228,629 328,130 04/13/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 06 Sell 7.55 2,181 16,467 360,979 04/08/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 01 Sell 7.74 3,800 29,412 363,160 04/05/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 30 Sell 7.52 300 2,256 366,960 04/01/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 22 Sell 7.5 4,800 36,000 377,560 03/24/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 17 Sell 7.53 3,604 27,138 382,360 03/21/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 14 Sell 7.02 1,500 10,530 385,964 03/16/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 09 Sell 7.04 2,822 19,867 387,464 03/14/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 04 Sell 7.08 14,504 102,688 390,286 03/08/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 24 Sell 7.46 13,752 102,590 432,383 02/28/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 18 Sell 7.83 38,297 299,866 446,135 02/23/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 15 Sell 8.1 47,502 384,766 484,432 02/17/22